3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Colorectal Neoplasms
43
Rectal Neoplasms
12
Colonic Neoplasms
12
Neoplasm Metastasis
6
Stomach Neoplasms
5
Pancreatic Neoplasms
5
Gallbladder Neoplasms
3
Colorectal Cancer Metastatic
3
Cholangiocarcinoma
3
Neutropenia
2
Neoplasms
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
mCRC
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Recurrence
1
Pretreated Metastatic Colorectal Cancer
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Nasopharyngeal Carcinoma
1
Microsatellite-stable Colorectal Cancer
1
Metastatic Gastric Adenocarcinoma
1
High-grade Extra Pulmonary Neuroendocrine Cancer
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Gastric and Gastroesophageal Junction Adenocarcinoma
1
Gastric Cancer Adenocarcinoma Metastatic
1
Gastric Adenocarcinoma
1
Interventions
Carboplatin
88
pembrolizumab
85
Paclitaxel
71
Cyclophosphamide
63
Capecitabine
38
Doxorubicin
37
Taxes
29
130-nm albumin-bound paclitaxel
29
Cisplatin
25
Albumin-Bound Paclitaxel
22
Epirubicin
21
Drug Therapy
21
Docetaxel
20
sacituzumab govitecan
19
olaparib
19
camrelizumab
18
atezolizumab
18
Gemcitabine
17
eribulin
16
durvalumab
16
Bevacizumab
16
Radiotherapy
15
toripalimab
14
Specimen Handling
14
Biopsy
13
Everolimus
12
Magnetic Resonance Spectroscopy
11
apatinib
10
Nivolumab
10
talazoparib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Triple Negative Breast Neoplasms
×
trifluridine tipiracil drug combination
×
Clear all
NCT04149444
2020-06-11
TACTIC
AHS Cancer Control Alberta
Phase 2
Withdrawn